Trial Profile

A phase 2 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 15 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 May 2024 According to a Dianthus Therapeutics media release, R&D expenses for the this quarter ended were $13.1 million, including $0.8 million of stock-based compensation, compared to $5.8 million for March 31, 2023, including $0.2 million of stock-based compensation. This increase in expenses was primarily driven by higher clinical, CMC costs and increased headcount to support DNTH103 Phase 1 and Phase 2 development, partially offset by lower pre-clinical costs.
09 May 2024 According to a Dianthus Therapeutics media release, the company expects to start this study in 2H, 2024.
12 Sep 2023 According to a Dianthus Therapeutics media release, the company expects to start this study in 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com